EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:EPRX

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/07/04	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/07/04	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/07	06:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/07	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/07	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/05	20:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/05	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/06/05	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/24	06:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/24	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/24	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	06:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/22	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/16	01:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/14	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/14	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/14	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/09	06:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/09	06:03	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/09	06:03	PR Newswire (US)	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/02	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/05/02	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/04/11	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/04/11	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/04/08	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/04/08	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc